关注
Naima Hammoudi
Naima Hammoudi
Postdoctoral fellow, MD Anderson Cancer Center
在 mdanderson.org 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential
H Pelicano, W Zhang, J Liu, N Hammoudi, J Dai, RH Xu, L Pusztai, ...
Breast cancer research 16, 1-16, 2014
2272014
Metabolic alterations in cancer cells and therapeutic implications
N Hammoudi, KBR Ahmed, C Garcia-Prieto, P Huang
Chinese journal of cancer 30 (8), 508, 2011
1282011
SF2312 is a natural phosphonate inhibitor of enolase
PG Leonard, N Satani, D Maxwell, YH Lin, N Hammoudi, Z Peng, ...
Nature chemical biology 12 (12), 1053-1058, 2016
912016
Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis
C Garcia-Prieto, KBR Ahmed, Z Chen, Y Zhou, N Hammoudi, Y Kang, ...
Journal of Biological Chemistry 288 (5), 3240-3250, 2013
652013
Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism
S Yuan, Y Lu, J Yang, G Chen, S Kim, L Feng, M Ogasawara, ...
Stem Cell Research & Therapy 6, 1-15, 2015
542015
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ...
Nature metabolism 2 (12), 1413-1426, 2020
532020
ENOblock does not inhibit the activity of the glycolytic enzyme enolase
N Satani, YH Lin, N Hammoudi, S Raghavan, DK Georgiou, FL Muller
PloS one 11 (12), e0168739, 2016
302016
Eradication of ENO1-deleted Glioblastoma through Collateral Lethality
YH Lin, N Satani, N Hammoudi, JJ Ackroyd, S Khadka, VC Yan, ...
BioRxiv, 331538, 2018
162018
The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues
F Pisaneschi, YH Lin, PG Leonard, N Satani, VC Yan, N Hammoudi, ...
Molecules 24 (13), 2510, 2019
142019
Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53
MA Ogasawara, J Liu, H Pelicano, N Hammoudi, CM Croce, MJ Keating, ...
Mitochondrion 31, 33-39, 2016
122016
Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers
VC Yan, CD Pham, ES Ballato, KL Yang, K Arthur, S Khadka, ...
Journal of Medicinal Chemistry 65 (20), 13813-13832, 2022
52022
Comparative pharmacology of a bis-pivaloyloxymethyl phosphonate prodrug inhibitor of enolase after oral and parenteral administration
VC Yan, Y Barekatain, YH Lin, N Satani, N Hammoudi, K Arthur, ...
ACS Pharmacology & Translational Science 6 (2), 245-252, 2023
22023
Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer
YH Lin, N Satani, N Hammoudi, F Pisaneschi, P Leonard, D Maxwell, ...
Molecular Cancer Therapeutics 16 (10_Supplement), A39-A39, 2017
22017
NAD+ biosynthesis as a collateral lethality target for precision oncology
FL Muller, P Deng, YH Lin, N Satani, N Hammoudi, G Mohapatra, ...
bioRxiv, 2022.12. 13.518967, 2022
12022
Potential role of reactive oxygen species in mediating glioblastoma stem cell differentiation
F Wang, S Yuan, G Chen, S Kim, N Hammoudi, L Feng, W Lu, JS Lee, ...
Cancer Research 72 (8_Supplement), 999-999, 2012
12012
Prodrugs of a 1-hydroxy-2-oxopiperidin-3-yl phosphonate enolase inhibitor for the treatment of ENO1-deleted cancers
VC Yan, CD Pham, ES Ballato, KL Yang, S Khadka, Y Barektain, ...
Cancer Research 83 (7_Supplement), 3097-3097, 2023
2023
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers (vol 2, pg 1413, 2020)
YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ...
NATURE METABOLISM 3 (1), 122-122, 2021
2021
Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers (Nature Metabolism,(2020), 2, 12,(1413-1426), 10.1038/s42255-020-00313-3)
YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ...
Nature Metabolism 3 (1), 122, 2021
2021
YIA19-004: Collateral Deletion of Glycolysis Genes Generates Selective Vulnerabilities to Inhibitors of Oxidative Phosphorylation
F Muller, YH Lin, N Satani, N Hammoudi
Journal of the National Comprehensive Cancer Network 17 (3.5), YIA19-004 …, 2019
2019
Collateral lethality: A new target for personalized oncology
YH Lin, N Hammoudi, N Satani, J Ackroyd, S Khadka, D Georgiou, ...
Cancer Research 78 (13_Supplement), 2831-2831, 2018
2018
系统目前无法执行此操作,请稍后再试。
文章 1–20